VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?
Viking Therapeutics (NASDAQ: VKTX) has quietly become one of the most closely watched small-cap names in the weight-loss drug trade. As of the last trading session on Friday, December 5, 2025, VKTX closed at $38.55, giving the company a market capitalization of roughly $4.3–4.4 billion. Viking Therapeutics InvestorRoom+1 Yet Wall Street’s consensus 12‑month price targets sit in the high‑$80s to around $100 per share, implying 120–160% upside from current levels. StockAnalysis+2Ticker Nerd+2 A fresh December 7 analysis from German outlet boerse-global.de went further, calling out a “striking valuation gap” between the sub‑$40 share price and analyst targets that suggest the